Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study

Acute graft versus host disease (aGVHD) remains a major problem after allogeneic hematopoietic stem cell transplantation. Standard frontline therapy for aGVHD involves corticosteroids. However, fewer than half of patients have a lasting complete response. The long-term mortality rate of steroid-refr...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yamin Tan, Haowen Xiao, Depei Wu, Yi Luo, Jianping Lan, Qifa Liu, Kang Yu, Jimin Shi, Jingsong He, Weiyan Zheng, Xiaoyu Lai, Yuanyuan Zhu, Kaili Du, Yishan Ye, Yanmin Zhao, Gaofeng Zheng, Yongxian Hu, Xiaoyan Han, Yanlong Zheng, Guoqing Wei, Zhen Cai, He Huang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2017-03-01
coleção:	OncoImmunology
Assuntos:	basiliximab etanercept hematopoietic stem cell transplantation steroid-refractory acute gvhd
Acesso em linha:	http://dx.doi.org/10.1080/2162402X.2016.1277307
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!